RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer

by Porta, Camillo
Published in Oncol Rev (2014)

RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane

by Porta, Camillo
Published in Oncol Rev (2020)

Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system

by Porta, Camillo
Published in ESMO Open (2020)

Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

by Porta, Camillo, Paglino, Chiara
Published 2010

ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics

by Porta, Camillo, Chiellino, Silvia
Published in Ann Transl Med (2016)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

by Rizzo, Mimma, Porta, Camillo
Published in Ther Adv Urol (2017)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

by Porta, Camillo, Paglino, Chiara, Mutti, Luciano
Published 2008

Targeting PI3K/Akt/mTOR Signaling in Cancer

by Porta, Camillo, Paglino, Chiara, Mosca, Alessandra
Published 2014

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial

by Porta, Camillo, Ganini, Carlo, Paglino, Chiara
Published in Transl Androl Urol (2012)

Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents

by Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Bonomi, Lucia
Published in ScientificWorldJournal (2007)

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or no...

by Porta, Camillo, Cosmai, Laura, Rizzo, Mimma, Melazzini, Mario
Published in Ann Transl Med (2019)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

by Guarini, Chiara, Grassi, Teresa, Pezzicoli, Gaetano, Porta, Camillo
Published in Int J Mol Sci (2021)

Renin angiotensin system deregulation as renal cancer risk factor

by Sobczuk, Paweł, Szczylik, Cezary, Porta, Camillo, Czarnecka, Anna M.
Published in Oncol Lett (2017)

Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research

by Negri, Francesca, Missale, Gabriele, Antoni, Anna Degli, Porta, Camillo
Published in Transl Oncol (2021)

Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?

by Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Ganini, Carlo, Pedrazzoli, Paolo
Published 2011

Insulin-like growth factor-1 signaling in renal cell carcinoma

by Tracz, Adam F., Szczylik, Cezary, Porta, Camillo, Czarnecka, Anna M.
Published in BMC Cancer (2016)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient

by Porta, Camillo, Ferrari, Alessandra, Czarnecka, Anna M., Szczylik, Cezary A.
Published in Front Pharmacol (2017)

Choosing the right cell line for renal cell cancer research

by Brodaczewska, Klaudia K., Szczylik, Cezary, Fiedorowicz, Michal, Porta, Camillo, Czarnecka, Anna M.
Published in Mol Cancer (2016)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer

by Internò, Valeria, Tucci, Marco, Pezzicoli, Gaetano, Silvestris, Franco, Porta, Camillo, Mannavola, Francesco
Published in Front Oncol (2020)

Large Extracellular Vesicles—A New Frontier of Liquid Biopsy in Oncology

by Pezzicoli, Gaetano, Tucci, Marco, Lovero, Domenica, Silvestris, Franco, Porta, Camillo, Mannavola, Francesco
Published in Int J Mol Sci (2020)